# C_2022333EN.01001201.xml

| 1.9.2022 | EN | Official Journal of the European Union | C 333/12 |
| --- | --- | --- | --- |

1.9.2022

EN

Official Journal of the European Union

C 333/12

---

Prior notification of a concentration

(Case M.10826 – GOLDMAN SACHS / NORGINE)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 333/11)

1.

This notification concerns the following undertakings:

| — | The Goldman Sachs Group, Inc. (‘Goldman Sachs’, United States of America); |
| --- | --- |

—

The Goldman Sachs Group, Inc. (‘Goldman Sachs’, United States of America);

| — | Norgine Europe B.V. together with its direct and indirect subsidiaries (‘the Norgine Group’ or the ‘Target’, Netherlands). |
| --- | --- |

—

Norgine Europe B.V. together with its direct and indirect subsidiaries (‘the Norgine Group’ or the ‘Target’, Netherlands).

Goldman Sachs will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Norgine (2).

The concentration is accomplished by way of purchase of shares.

2.

| — | Goldman Sachs is a global investment banking, securities and investment management firm that provides a range of banking, securities and investment services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals, |
| --- | --- |

—

Goldman Sachs is a global investment banking, securities and investment management firm that provides a range of banking, securities and investment services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals,

| — | The Norgine Group, which is headquartered in the Netherlands, is a European specialist pharmaceutical company that develops, manufactures, and markets pharmaceutical goods mainly for the following therapeutic areas: gastroenterology, hepatology, emergency care, haematology, obstetrics, cardiology, oncology, urology, and neurology. |
| --- | --- |

—

The Norgine Group, which is headquartered in the Netherlands, is a European specialist pharmaceutical company that develops, manufactures, and markets pharmaceutical goods mainly for the following therapeutic areas: gastroenterology, hepatology, emergency care, haematology, obstetrics, cardiology, oncology, urology, and neurology.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (3) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10826 – GOLDMAN SACHS / NORGINE

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  Prior to completion of the Transaction, Norgine Ventures B.V. and its direct and indirect subsidiaries (‘Norgine Ventures’) will be carved out from the Norgine Group, which is the Target of the Transaction.

2

(3)  OJ C 366, 14.12.2013, p. 5.

3

---